LY iTECH(SZ:002600) Ju Chao Zi Xun·2026-01-06 13:48Core Insights - Qiang Brain Technology has completed approximately 2 billion yuan in financing, marking the second-largest funding round in the global brain-computer interface (BCI) sector, following Neuralink [1] - The investment round included prominent firms such as IDG Capital and Huaden International, as well as strategic investments from companies like Weir Shares and Runze Technology [1] - Qiang Brain Technology is recognized as one of the leading companies in the BCI field, having received FDA and CE certifications for its products and being one of the largest investors in BCI research and development globally [1] Company Overview - Founded in February 2015, Qiang Brain Technology originated from Harvard University's innovation lab and focuses on non-invasive BCI technology [1] - The company has launched several products, including smart bionic limbs and brain-machine intelligent sleep devices [1] - Qiang Brain Technology has undergone multiple funding rounds since 2016 and is considering an IPO in the Hong Kong or A-share market [1] Industry Perspective - Neuralink remains the leading company in the BCI sector with a valuation of 9 billion USD and plans to initiate large-scale production of BCI devices by 2026 [2] - The BCI technology is expected to transition from medical necessity to AI applications, indicating a potential commercialization phase starting in 2026 [2] - The A-share market has seen significant interest in BCI-related stocks, with companies like Innovation Medical and Aipeng Medical experiencing consecutive trading limit increases [2] Market Trends - The BCI market is currently in its early commercialization stage, with a focus on thematic investments [2] - There is a distinction between invasive and non-invasive technology paths, with some invasive products already approved for market release, while non-invasive technologies have a clearer commercialization path [2] - Scarcity in hardware and materials related to electrodes, chips, and membranes presents investment opportunities in the BCI sector [2]